From the link in my post:
The company began a trial in September 2013 to see if its sleep therapy would provide an extra benefit to people who suffered from heart failure. The 1325-person trial across Europe and Australia, known as SERVE-HF, sought to show that the therapy would leave patients more likely to avoid death, or hospital visits, due to heart failure complications. Heart failure is caused when the muscles in the heart are too weak to pump blood around the body effectively.
However in a statement released on Wednesday afternoon, ResMed said patients who received the therapy showed an increased risk of death.
Read more: http://www.smh.com.au/business/resmed-heart-failure-trial-puts-patients-at-risk-20150513-gh10qs.html#ixzz3frxhkMZK
and the etrade post refers to the above article dated 13 May.
What's this?, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$37.28 |
Change
0.200(0.54%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $37.50 | $37.55 | $37.15 | $17.93M | 480.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3363 | $37.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $37.30 | 1001 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
